tradingkey.logo

LENSAR Inc

LNSR
查看詳細走勢圖
12.045USD
+0.035+0.29%
交易中 美東報價延遲15分鐘
143.76M總市值
虧損本益比TTM

LENSAR Inc

12.045
+0.035+0.29%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+0.29%

5天

+4.65%

1月

+22.53%

6月

-2.94%

今年開始到現在

+34.73%

1年

+56.43%

查看詳細走勢圖

TradingKey LENSAR Inc股票評分

單位: USD 更新時間: 2025-12-19

操作建議

LENSAR Inc當前公司基本面數據相對穩定,增長潛力很大。當前估值合理,在醫療設備與耗材行業排名104/208位。機構持股佔比非常高,近一個月多位分析師給出公司評級為持有。最高目標價15.00。中期看,股價處於平穩狀態。近一個月,市場表現很強,技術面和基本面綜合得分較高,很強的走勢得到基本面和技術面的印證。目前股價在壓力位和支撐位之間,可以做區間波段操作。

LENSAR Inc評分

相關信息

行業排名
104 / 208
全市場排名
236 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
持有
評級
15.000
目標均價
+34.05%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

LENSAR Inc亮點

亮點風險
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
業績高增長
公司營業收入穩步增長,連續3年增長51.29%
業績增長期
公司處於發展階段,最新年度總收入53.49M美元
利潤高增長
公司淨利潤處於行業前列,最新年度總收入53.49M美元
估值合理
公司最新PE估值-2.75,處於3年歷史合理位
機構減倉
最新機構持股5.64M股,環比減少1.71%
先鋒集團持倉
明星投資者先鋒集團持倉,最新持倉507.60K股
活躍度降低
近期活躍度降低,過去20天平均換手率-0.07

LENSAR Inc新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

LENSAR Inc簡介

LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
公司代碼LNSR
公司LENSAR Inc
CEOCurtis (Nicholas T)
網址https://www.lensar.com/

常見問題

LENSAR Inc(LNSR)的當前股價是多少?

LENSAR Inc(LNSR)的當前股價是 12.045。

LENSAR Inc 的股票代碼是什麼?

LENSAR Inc的股票代碼是LNSR。

LENSAR Inc股票的52週最高點是多少?

LENSAR Inc股票的52週最高點是17.310。

LENSAR Inc股票的52週最低點是多少?

LENSAR Inc股票的52週最低點是7.250。

LENSAR Inc的市值是多少?

LENSAR Inc的市值是143.76M。

LENSAR Inc的淨利潤是多少?

LENSAR Inc的淨利潤為-31.40M。

現在LENSAR Inc(LNSR)的股票是買入、持有還是賣出?

根據分析師評級,LENSAR Inc(LNSR)的總體評級為持有,目標價格為15.000。

LENSAR Inc(LNSR)股票的每股收益(EPS TTM)是多少

LENSAR Inc(LNSR)股票的每股收益(EPS TTM)是-4.374。
KeyAI